Biopharmaceutical benchmarks - 2003

Nature Biotechnology

Volumn 21, Issue 8, 2003, Pages 865-870

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN; CYTOKINE; DNA VACCINE; ENZYME; ETANERCEPT; FIBRINOLYTIC AGENT; FOLLITROPIN; GROWTH FACTOR; HORMONE DERIVATIVE; HUMAN INSULIN; IMIGLUCERASE; INFLIXIMAB; INFUSE; INSULIN ASPART; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; INTERFERON; ISOPHANE INSULIN; LEPIRUDIN; MACROGOL; MONOCLONAL ANTIBODY; NEUTRAL INSULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OSTEOGENIC PROTEIN 1; PALIVIZUMAB; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROFOLLITROPIN; VACCINE;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

BENCHMARKING; BIOPHARMACEUTICS; DRUG APPROVAL; DRUG COMPOUNDING; DRUG INDUSTRY; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES;

EID: 0043208919     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0803-865     Document Type: Review

References (11)

1. Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 18, 831-833 (and associated 6 page pullout supplement) (2000).
2. Holmer, A.F. New biotechnology medicines in development, 2002. (Pharmaceutical Research and Manufacturers of America, Washington, D.C.) http://www.phrma.org/publications/publications//2002-10-21.601.pdf (October 2002).
3. Robinson, K. An industry comes of age. Biopharm Int. 15, (11) 20-24 (2002).
4. World Health Organization. Hepatitis B Fact Sheet. (WHO, Geneva, Switzerland) http://www.who.int/inf-fs/en/fact204.html (October 2000).
5. Pfeifer, A. & Verma, I. Gene therapy: promises and problems. Ann. Rev. Genomics Hum. Genet. 2, 177-211 (2001).
6. Pouton, C. & Seymour, L. Key issues in non-viral gene delivery. Adv. Drug Del. Rev. 46, 187-203 (2001).
7. Lou, D. & Saltzman, W. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33-37 (2000).
8. Thompson, L. Human gene therapy. Harsh lessons, high hopes. FDA Consumer Magazine, http://www.fda.gov/fdac/features/2000/500_gene.htm I, (Sept.-Oct. 2000).
9. Check, E. Cancer risk prompts US to curb gene therapy. Nature, 422, 7 (2003).
10. Akhtar, S. et al. The delivery of antisense therapeutics. Adv. Drug Del. Rev. 44, 3-21 (2000).
11. Bouchie, A. Tissue engineering firms go under. Nat. Biotechnol. 20, 1178-1179, 2001.